Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures
Top Cited Papers
Open Access
- 1 January 2012
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Surgery
- Vol. 4 (4), 87-95
- https://doi.org/10.4240/wjgs.v4.i4.87
Abstract
Malignant ascites indicates the presence of malignant cells in the peritoneal cavity and is a grave prognostic sign. While survival in this patient population is poor, averaging about 20 wk from time of diagnosis, quality of life can be improved through palliative procedures. Selecting the appropriate treatment modality remains a careful process, which should take into account potential risks and benefits and the life expectancy of the patient. Traditional therapies, including paracentesis, peritoneovenous shunt placement and diuretics, are successful and effective in varying degrees. After careful review of the patient’s primary tumor origin, tumor biology, tumor stage, patient performance status and comorbidities, surgical debulking and intraperitoneal chemotherapy should be considered if the benefit of therapy outweighs the risk of operation because survival curves can be extended and palliation of symptomatic malignant ascites can be achieved in select patients. In patients with peritoneal carcinomatosis who do not qualify for surgical cytoreduction but suffer from the effects of malignant ascites, intraperitoneal chemotherapy can be safely and effectively administered via laparoscopic techniques. Short operative times, short hospital stays, low complication rates and ultimately symptomatic relief are the advantages of laparoscopically administering heated intraperitoneal chemotherapy, making it not only a valuable treatment modality but also the most successful treatment modality for achieving palliative cure of malignant ascites.Keywords
This publication has 48 references indexed in Scilit:
- Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignanciesJournal of Surgical Oncology, 2009
- Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi‐institutional retrospective analysis in 52 patientsJournal of Surgical Oncology, 2009
- Vascular permeability, vascular hyperpermeability and angiogenesisAngiogenesis, 2008
- Pattern and prognostic factors in patients with malignant ascites: a retrospective studyAnnals Of Oncology, 2007
- Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascitesEuropean Journal of Surgical Oncology, 2006
- Malignant ascites: Systematic review and guideline for treatmentEuropean Journal Of Cancer, 2006
- Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future DirectionsAnnals of Surgical Oncology, 2005
- Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosisEuropean Journal of Surgical Oncology, 2001
- Ascitic fluid analysis in malignancy-related ascitesHepatology, 1988
- Zur FettresorptionVirchows Archiv, 1863